Contact information for health care professionals
This content is intended for US health care professionals only. By clicking "yes" I am confirming that I am a US health care professional.
If you are not a healthcare professional, please click here.
Please use the form below to submit your questions regarding the CliniMACS® CD34 Reagent System, or contact us at 001 617 218 0061.
If you wish information on reimbursement, please go to the reimbursement resource area.
Please note: the CliniMACS CD34 Reagent System is approved by the U.S. FDA. If you are not an US resident and wish further information on the system, please visit our corporate contact site.
Humanitarian Device
Authorized by U.S. Federal Law for use in the treatment of patients with acute myeloid leukemia (AML) in first complete remission. The effectiveness of the device for this use has not been demonstrated.
Indications for Use
The CliniMACS® CD34 Reagent System is indicated for processing hematopoietic progenitor cells collected by apheresis (HPC, Apheresis) from an allogeneic, HLA-identical, sibling donor to obtain a CD34+ cell-enriched population for hematopoietic reconstitution following a myeloablative preparative regimen without the need for additional graft versus host disease (GVHD) prophylaxis in patients with acute myeloid leukemia (AML) in first morphologic complete remission.
Contraindications
Do not use CD34+ cells prepared with CliniMACS CD34 Reagent System in patients with known hypersensitivity to murine (mouse) proteins or iron dextran.
Rx only